Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Astellas Pharma Inc. (4503.T)
Tokyo, JP
Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. Its extensive product lineup addresses critical health needs, including various oncology treatments such as XTANDI for prostate cancer, XOSPATA, an FLT3 inhibitor for specific relapsed or refractory acute myeloid leukemia, and PADCEV for advanced urothelial cancer. For urological conditions, Astellas offers Betanis/Myrbetriq/BETMIGA to manage symptoms of overactive bladder, mirabegron for neurogenic detrusor overactivity in children, and Vesicare for OAB. Other notable pharmaceuticals include Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, Evrenzo for anemia associated with chronic kidney disease, and the immunosuppressants Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ transplant rejection. The company also markets Funguard/MYCAMINE, an antifungal agent. Astellas actively fosters innovation through numerous strategic collaborations and partnerships. These include clinical trial agreements with pharmaceutical giants like Merck & Co., Inc. and CytomX Therapeutics, Inc. Demonstrating a broader approach to health, they collaborate with BANDAI NAMCO Entertainment Inc. on developing a smartphone exercise support application. In the realm of scientific discovery, Astellas maintains a research alliance with Harvard University for joint therapeutic and technological advancements. Further research initiatives involve Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies leveraging their Antibody Warhead Enabling platform, an agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694, and a collaboration with Cytokinetics, Incorporated. A significant strategic alliance and license agreement exist with Minovia Therapeutics Ltd. to research, develop, and commercialize cell therapies for mitochondrial dysfunction.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.49% | +0.79% | +2.28% | -12.24% | +15.95% | +7.18% | +59.76% | +0.84% | +27.01% | +52.86% | +246.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 9 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+11.9% ★ Q1'26: +17.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+474.4% ★ Q1'26: -42.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+22.7% ★ Q1'26: +35.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+19.6% ★ Q1'26: +14.5% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+15.4% ★ Q1'26: +13.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.92× Q1'26: 1.10× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 13 Rev. Ana. 12 EPS Ana. |
Mar 2027 13 Rev. Ana. 11 EPS Ana. |
Mar 2028 12 Rev. Ana. 11 EPS Ana. |
Mar 2029 11 Rev. Ana. 9 EPS Ana. |
Mar 2030 7 Rev. Ana. 3 EPS Ana. |
Mar 2031 7 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.25T
est: 1.24T (+0.6%)
|
1.37T
est: 1.39T (-1.3%)
|
1.31T
est: 1.32T (-1.0%)
|
1.30T
est: 1.30T (-0.2%)
|
1.31T
est: 1.30T (+0.3%)
|
1.30T
est: 1.27T (+2.2%)
|
1.25T
est: 1.26T (-0.8%)
|
1.30T
est: 1.32T (-1.6%)
|
1.52T
est: 1.51T (+0.7%)
|
1.60T
est: 1.70T (-5.8%)
|
1.91T
est: 1.90T (+0.4%)
|
2.13T
2.09T – 2.20T
+11.6% YoY
|
2.24T
2.20T – 2.35T
+5.6% YoY
|
2.08T
1.97T – 2.23T
-7.4% YoY
|
1.84T
1.84T – 1.85T
-11.2% YoY
|
1.71T
1.65T – 1.81T
-7.4% YoY
|
1.77T
1.71T – 1.88T
+3.9% YoY
|
| EBITDA |
292.35B
est: 191.49B (+52.7%)
|
338.69B
est: 214.60B (+57.8%)
|
337.61B
est: 204.50B (+65.1%)
|
336.68B
est: 201.14B (+67.4%)
|
345.87B
est: 201.04B (+72.0%)
|
333.88B
est: 196.58B (+69.8%)
|
323.58B
est: 194.44B (+66.4%)
|
297.83B
est: 203.42B (+46.4%)
|
337.39B
est: 232.73B (+45.0%)
|
282.45B
est: 393.85B (-28.3%)
|
462.67B
est: 440.84B (+5.0%)
|
491.93B
483.28B – 509.45B
+11.6% YoY
|
519.37B
509.61B – 543.03B
+5.6% YoY
|
480.87B
456.88B – 515.68B
-7.4% YoY
|
426.97B
426.87B – 427.07B
-11.2% YoY
|
395.42B
382.09B – 418.53B
-7.4% YoY
|
410.74B
396.89B – 434.74B
+3.9% YoY
|
| EBIT |
226.87B
est: 94.29B (+140.6%)
|
269.50B
est: 105.67B (+155.0%)
|
273.81B
est: 100.70B (+171.9%)
|
271.82B
est: 99.04B (+174.4%)
|
282.42B
est: 98.99B (+185.3%)
|
267.48B
est: 96.80B (+176.3%)
|
250.93B
est: 95.74B (+162.1%)
|
218.15B
est: 100.17B (+117.8%)
|
231.65B
est: 114.60B (+102.1%)
|
124.61B
est: 249.33B (-50.0%)
|
263.54B
est: 279.08B (-5.6%)
|
311.42B
305.94B – 322.50B
+11.6% YoY
|
328.79B
322.61B – 343.77B
+5.6% YoY
|
304.42B
289.23B – 326.45B
-7.4% YoY
|
270.29B
270.23B – 270.36B
-11.2% YoY
|
250.32B
241.88B – 264.95B
-7.4% YoY
|
260.02B
251.25B – 275.21B
+3.9% YoY
|
| Net Income |
135.86B
est: 120.77B (+12.5%)
|
193.69B
est: 149.20B (+29.8%)
|
218.70B
est: 176.44B (+23.9%)
|
164.68B
est: 159.22B (+3.4%)
|
222.27B
est: 204.77B (+8.5%)
|
195.41B
est: 205.32B (-4.8%)
|
120.59B
est: 168.84B (-28.6%)
|
124.09B
est: 168.12B (-26.2%)
|
98.71B
est: 151.84B (-35.0%)
|
17.05B
est: 21.52B (-20.8%)
|
50.75B
est: 18.40B (+175.8%)
|
291.54B
230.46B – 406.32B
+1,484.4% YoY
|
347.06B
278.74B – 445.18B
+19.0% YoY
|
326.31B
224.99B – 481.88B
-6.0% YoY
|
247.52B
122.97B – 433.43B
-24.1% YoY
|
222.07B
212.34B – 238.94B
-10.3% YoY
|
228.23B
218.23B – 245.57B
+2.8% YoY
|
| SGA |
452.52B
est: 531.99B (-14.9%)
|
500.36B
est: 596.19B (-16.1%)
|
470.78B
est: 568.14B (-17.1%)
|
478.33B
est: 558.79B (-14.4%)
|
490.26B
est: 558.53B (-12.2%)
|
499.30B
est: 546.14B (-8.6%)
|
504.32B
est: 540.19B (-6.6%)
|
548.84B
est: 565.15B (-2.9%)
|
630.27B
est: 646.56B (-2.5%)
|
740.11B
est: 729.38B (+1.5%)
|
843.03B
est: 816.40B (+3.3%)
|
911.02B
895.00B – 943.45B
+11.6% YoY
|
961.83B
943.76B – 1.01T
+5.6% YoY
|
890.54B
846.10B – 955.00B
-7.4% YoY
|
790.72B
790.53B – 790.90B
-11.2% YoY
|
732.29B
707.60B – 775.08B
-7.4% YoY
|
760.65B
735.01B – 805.10B
+3.9% YoY
|
| EPS |
61.50
est: 67.20 (-8.5%)
|
89.75
est: 83.02 (+8.1%)
|
103.69
est: 98.18 (+5.6%)
|
81.11
est: 88.60 (-8.4%)
|
115.05
est: 113.94 (+1.0%)
|
104.15
est: 114.25 (-8.8%)
|
64.93
est: 93.95 (-30.9%)
|
67.08
est: 93.55 (-28.3%)
|
54.24
est: 84.49 (-35.8%)
|
9.50
est: 12.01 (-20.9%)
|
28.35
est: 10.08 (+181.3%)
|
157.09
128.24 – 226.10
+1,458.9% YoY
|
183.78
155.10 – 247.72
+17.0% YoY
|
183.44
125.20 – 268.14
-0.2% YoY
|
140.07
68.42 – 241.18
-23.6% YoY
|
123.57
118.15 – 132.96
-11.8% YoY
|
127.00
121.43 – 136.65
+2.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Naoki Okamura | President, Chief Executive Officer & Director | 428M | male |
| Katsuyoshi Sugita | Executive Vice President, Chief People Officer & Representative Director | 185M | male |
| Leticia Delgado-Herrera | Vice President and Rx+ M&D Head | — | female |
| Nobuaki Tanaka | President of Japan Commercial & Senior Corporate Executive | — | male |
| Nobue Yasuda | General Manager of Finance & Accounting Department | — | — |
| Nobuko Kato | Chief Communications & Investor Relations Officer | — | female |
| Tatjana Dragovic | General Counsel, Chief Ethics & Compliance Officer | — | female |
| Atsushi Kitamura | Senior Executive Officer & Chief Financial Officer | — | male |
| Yoshitsugu Shitaka | Chief Scientific Officer & Senior Managing Executive Officer | — | male |
| Jun Kono | Senior Executive Officer & Head of Japan Commercial | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4503.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
